Sending letters to encourage guideline-directed practice in the management of chronic kidney disease to either patients or their general practitioner does not improve prescription rates, shows trial.

Yale School of Medicine researchers have identified a biomarker panel that improves the assessment of chronic kidney disease ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

The diabetic nephropathy market is driven by the growing burden of diabetes and the increasing demand for effective treatments for kidney disease. Advances in therapeutics, including new drug classes ...

Bagsværd, Denmark, 10 June – Novo Nordisk today announced that new data from its industry-leading portfolio in metabolic and cardiovascular health will be showcased at the upcoming American Diabetes ...

During a session at the Heart in Diabetes CME Conference, speakers highlighted four papers recently published in Circulation ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...